Trusted Global CDMO Partner Delivering End-to-End Pharma Manufacturing & Development Solutions.

Contact Supplier

Evonik Health Care is the innovation hub for leading life science companies

ACCESS ALL DATA
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

3 API Suppliers, 2 NDC API, 1 Listed Suppliers

3 API Suppliers
2 NDC API
1 Listed Suppliers

DEVELOPMENTS

8 Drugs in Development

8 Drugs in Development

FINISHED DOSAGE FORMULATIONS

18 FDF Dossiers, 4 FDA Orange Book, 9 Europe, 2 Canada, 3 Listed Dossiers

18 FDF Dossiers
4 FDA Orange Book
9 Europe
2 Canada
3 Listed Dossiers

DIGITAL CONTENT

1 Data Compilation #PharmaFlow, 19 News #PharmaBuzz

media
1 Data Compilation #PharmaFlow
19 News #PharmaBuzz

GLOBAL SALES INFORMATION

1 Annual Reports

globalSalesInformation
1 Annual Reports

MARKET PLACE

1 APIs, 5 FDF Dossiers

marketPlace
1 APIs
5 FDF Dossiers

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

0INTERMEDIATES

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

DRUG PRODUCT COMPOSITIONS

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

API/FDF Prices: Book a Demo

API REF. PRICE (USD/KG)

$ 0

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Regulatory FDF Prices

MARKET PLACE

API

FDF

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

API SUPPLIERS

01

Country

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

BioProcess International US West

Not Confirmed

02

Vannsh Life Sciences

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

BioProcess International US West

Not Confirmed

03

Darmerica

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

BioProcess International US West

Not Confirmed

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

NDC API

01

DARMERICA, LLC

U.S.A

BioProcess International US West

Not Confirmed

02

PROVIS BIOLABS PRIVATE LIMITED

Country

BioProcess International US West

Not Confirmed

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Suppliers

01

Vannsh Life Sciences

India

BPI West

Not Confirmed

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Drugs in Development

01 Sanofi

France

BioProcess International US West

Not Confirmed

Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

Lead Product(s) : Dexamethasone, Fludarabine Phosphate, Cytarabine, Daunorubicin, Idarubicin Hydrochloride

Therapeutic Area : Oncology

Highest Development Status : Phase II

Partner/Sponsor/Collaborator : Undisclosed

Deal Size : Inapplicable

Deal Type : Inapplicable

DEALS_DEV

Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute L...

Details : Isatuximab is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Precursor Cell Lymphoblastic Leukemia-Lymphoma.

Product Name : Undisclosed

Product Type : Antibody, Unconjugated

Upfront Cash : Inapplicable

March 04, 2019

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDF Dossiers

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDA Orange Book

01

JAZZ PHARMS

Ireland

BioProcess International US West

Not Confirmed

02

MERCK

U.S.A

BioProcess International US West

Not Confirmed

03

SERVIER PHARMA LLC

France

BioProcess International US West

Not Confirmed

04

SIGMA TAU

U.S.A

BioProcess International US West

Not Confirmed

France

BioProcess International US West

Not Confirmed

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Canada

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Dossiers

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

US drug shortages reduce 16% YoY in Q1 2025; CNS drugs, antimicrobials face highest scarcities

The pharmaceutical industry in the United States continued to grapple with drug shortages during the first quarter (Q1) of 2025. According to the American Society of Health‑System Pharmacists (ASHP), the total number of active shortages stood at 270 as of March 31, 2025 — only slightly below the 277 reported in September 2024, but down 16.4 percent from an all‑time high of 323 reported in Q1 2024.These numbers imply that while dramatic surges in drug shortages may have subsided, underlying vulnerabilities in manufacturing, supply chains, and raw‑material sourcing continue to frustrate efforts towards a durable resolution.A deeper analysis of these drug scarcities reveals that 41 percent of the 270 active shortages first emerged in 2022 or earlier. This implies that many of the current disruptions have become chronic in nature and are exerting pressure on pharmacy operations. View Our Interactive Dashboard on Drug Shortages So Far in 2025 (Free Excel Available)CNS drugs dominate with 49 meds in short supply; antimicrobials face shortage of 39 drugsClass‑specific analysis reveals that central nervous system (CNS) agents remained the most disrupted category, with 49 distinct CNS drugs having faced scarcities during Q1. This group spans anxiolytics (anti-anxiety drugs) such as clonazepam and flurazepam, sedatives like lorazepam and midazolam, and stimulants such as methylphenidate and lisdexamfetamine. These shortages pose two challenges — controlling seizures and managing sedation in acute care settings. After CNS agents, antimicrobials was the second‑largest category, with shortages affecting 39 drugs. Key antibacterial and anti-fungal agents such as cefotaxime sodium powder for injection, clindamycin phosphate, rifampin, and metronidazole find themselves on ASHP’s active‑shortage roster, threatening both routine hospital protocols and emergency sepsis management.Fluids and electrolytes occupied the third spot, with 29 items facing shortage in Q1 2025. Hormone agents, including insulin analogs, ranked fourth with 24 drugs in short supply.Chemotherapy medications rounded out the top five categories, with 23 antineoplastic agents (a broad class of medications used to treat cancer) flagged as actively constrained in Q1 2025. Notable shortages included azacitidine, carboplatin, methotrexate, and streptozocin. View Our Interactive Dashboard on Drug Shortages So Far in 2025 (Free Excel Available) US faces 26 new shortages; Pharmacopeia list warns of 100 vulnerable medicationsThe first quarter saw the emergence of 26 new shortage declarations, emphasizing that even drugs previously deemed reliably sourced can fall into scarcity. The US has been facing a shortage of attention deficit hyperactivity disorder (ADHD) drugs since 2022. The new shortages included ADHD transdermal patch methylphenidate, peginterferon alfa‑2a (Pegasys) used in chronic hepatitis B and C, and bacitracin ophthalmic ointment.The fragility of the pharmaceutical supply chains has been particularly evident in the aftermath of natural disasters. Hurricane Helene’s flooding at Baxter’s Marion, North Carolina, facility deeply affected IV‑solution supply lines. Baxter supplies roughly 60 percent of the US’ IV fluids and the ASHP report listed “hurricane” as the reason behind nine percent of drug shortages, as of January 2025.Regulatory and policy interventions continue to evolve. The US Pharmacopeia’s inaugural Vulnerable Medicines List, launched in 2025, identifies 100 drugs at the highest risk of future shortages, with a particular focus on injectables (comprising 71 percent of the list) and essential hospital care.Antibiotics, medications for pain management and oncology are the other drugs on the list. Although 61 percent of these vulnerable medicines were not in active shortage at the time of listing, their inclusion is intended to galvanize manufacturers and purchasing organizations to bolster inventories.Meanwhile, the Government Accountability Office in the US has called on the Department of Health and Human Services (HHS) to establish a formal coordination mechanism, warning that elimination of the HHS supply‑chain coordinator role in May 2025 risks fragmenting federal response efforts. View Our Interactive Dashboard on Drug Shortages So Far in 2025 (Free Excel Available) Global shortages mirror US patterns; Europe launches monitoring platform Globally, we notice comparable trends. For instance, Europe has rolled out the European Shortages Monitoring Platform (ESMP) this year in order to centralize shortage reporting across member states. Critical‑medicine shortages in the EU — in areas such as oncology, ADHD, and critical care analgesics — mirror US patterns. The European Medicines Agency’s shortage list currently holds 37 human drugs.According to Health Canada’s May 12, 2025 update, its Tier 3 list had 18 drug shortages that are considered to have the greatest impact on Canada’s drug supply and health‑care system. Tier 3 designation is based on medical necessity and minimal availability of alternatives.In hematology and oncology, scarcity of essential drugs like Oncaspar for acute lymphoblastic leukemia, idarubicin and lomustine for leukemias and brain tumors, anagrelide for thrombocythemia, and preservative‑free methotrexate for various malignancies underscore the impact these drug shortages can have on treatment. View Our Interactive Dashboard on Drug Shortages So Far in 2025 (Free Excel Available) Our viewThe global pharma supply chain is dealing with a fresh wave of uncertainties, especially with the likelihood of tariffs on drugs imported into the US. Analysts warn that the proposed pharmaceutical tariffs could exacerbate supply issues.Over 50 percent of drugs used in the US are manufactured abroad. Generic sterile injectable drugs — like chemotherapy medications and IV saline — are particularly vulnerable due to their complex manufacturing processes and low profit margins. Generic drugs (which account for 90 percent of prescriptions filled in the US) could face increased pressure, as many rely on raw materials from China and India. This could result in more severe drug shortages in the future.

Impressions: 4608

NEWS #PharmaBuzz

Kwality Pharma gains on receiving nod for PEGylated-Asparaginase

26 Nov 2024

// BUSINESS STD

Servier's Biologic Asparlas (Calaspargase Pegol-mknl) Receives Approval in the U.S.

29 Nov 2023

// FDA

Sigma's Biologic Oncaspar (Pegaspargase) Receives Approval in the U.S.

22 Dec 2022

// FDA

Analysis Suggest Pediatric-Inspired Regimens Lead to Higher Survival in Patient

12 Dec 2022

// PRNEWSWIRE

Servier Pharma's Biologic Asparlas (Calaspargase Pegol- mknl) Receives Approval in the U.S.

21 Dec 2021

// FDA

Jazz Presents Positive Interim Phase 2/3 Results of Rylaze in ALL and LBL

11 Dec 2021

// PRNEWSWIRE

Global Sales Information

Do you need Business Intel? Ask us

Annual Reports

01 Brand Name : Leunase

Asparaginase

BioProcess International

Not Confirmed

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Market Place

Do you need sourcing support? Ask us

APIs

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDF DOSSIERS

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

ABOUT THIS PAGE

Privacy policy
Terms and conditions
Disclaimers
Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

Find Peg L asparaginase manufacturers, exporters & distributors on PharmaCompass

ACCESS ALL DATA

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

3 API Suppliers

2 NDC API

1 Listed Suppliers

DEVELOPMENTS

8 Drugs in Development

FINISHED DOSAGE FORMULATIONS

18 FDF Dossiers

4 FDA Orange Book

9 Europe

2 Canada

3 Listed Dossiers

DIGITAL CONTENT

1 Data Compilation #PharmaFlow

19 News #PharmaBuzz

GLOBAL SALES INFORMATION

1 Annual Reports

MARKET PLACE

1 APIs

5 FDF Dossiers

ACTIVE PHARMA INGREDIENTS

0INTERMEDIATES

REF. STANDARDS OR IMPURITIES

FINISHED DOSAGE FORMULATIONS

DRUG PRODUCT COMPOSITIONS

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

API REF. PRICE (USD/KG)

$ 0

GLOBAL SALES INFORMATION

MARKET PLACE

DIGITAL CONTENT

01

02

03

01

02

PROVIS BIOLABS PRIVATE LIMITED

PROVIS BIOLABS PRIVATE LIMITED

01

01

02

03

Children's Oncology Group

Children's Oncology Group

04

05

06

Children's Oncology Group

Children's Oncology Group

07

08

Children's Oncology Group

Children's Oncology Group

09

10

01

02

03

04

01

02

03

04

05

06

07

08

09

01

Brand Name : Leunase

Brand Name : Leunase

What are you looking for?